Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Hyun Ae
Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC
Abstract Background: Epidermal growth factor receptor (EGFR) exon 20 insertion mutations in non-small cell lung cancer (NSCLC) represent a distinct molecular subset with limited response to conventional tyrosine kinase inhibitors (TKIs). Mobocertinib, a targeted EGFR exon 20 inhibitor, shows clinical activity, yet the genomic resistance mechanisms remain poorly characterized, particularly through circulating tumor DNA (ctDNA) analysis.
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study | BMC Cancer | Full Text
We conducted a retrospective analysis on patients diagnosed as NSCLC with AGAs at the Samsung Medical Center from January 2019 to May 2023. All patients had histologically confirmed NSCLC, were identified as harboring AGAs including EGFR exon 20 insertion (E20I), HER2 mutation (mHER2), RET fusion (RET), or MET exon 14 skipping (METex14), and received either platinum doublets or platinum doublets with ICIs as a first-line therapy.
Frontiers | Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma
SYSTEMATIC REVIEW article Front. Immunol. Sec.
A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)
Purpose: This study evaluated the efficacy and safety of nivolumab plus gemcitabine in patients with platinum failed NPC. Patients and Methods: This is a phase II, multicenter, open-label, single-arm study. Patients with recurrent or metastatic NPC received nivolumab 3 mg/kg and gemcitabine 1,250 mg/m2 every 2 weeks until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS).
Peroxiredoxin-1 Tyr194 phosphorylation regulates LOX-dependent extracellular matrix remodelling in breast cancer - British Journal of Cancer
References 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. PubMed Article Google Scholar 2. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012;31:195–208. PubMed Article Google Scholar 3. Friedl P, Locker J, Sahai E, Segall JE. Classifying collective cancer cell invasion. Nat. Cell Biol. 2012;14:777–83. PubMed Article CAS Google Scholar 4.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Hyun
Contact Hyun, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack